<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="1.1d1" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher">REMEDIUM</journal-id><journal-title-group><journal-title>REMEDIUM</journal-title></journal-title-group><issn publication-format="print">1561-5936</issn><issn publication-format="electronic">2658-3534</issn><publisher><publisher-name>Joint-Stock Company Chicot</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1264</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>V Rossii odobren novyy preparat dlya lecheniya rasprostranennogo i metastaticheskogo raka molochnoy zhelezy</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Article</surname><given-names>Editorial</given-names></name><bio></bio><email>noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff id="aff-1"></aff><pub-date date-type="epub" iso-8601-date="2018-12-06" publication-format="electronic"><day>06</day><month>12</month><year>2018</year></pub-date><issue>6</issue><fpage>43</fpage><lpage>43</lpage><history><pub-date date-type="received" iso-8601-date="2022-03-18"><day>18</day><month>03</month><year>2022</year></pub-date></history><permissions><copyright-statement>Copyright © 2018,</copyright-statement><copyright-year>2018</copyright-year></permissions><kwd-group xml:lang="ru"><kwd>кискали</kwd><kwd>рибоциклиб</kwd><kwd>постменопауза</kwd><kwd>РМЖ</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Инструкция по медицинскому применению препарата Кискали® ЛП-004670 от 25.01.2018.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Каприн АД, Старшинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2016 (Заболеваемость и смертность). М., 2018.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Ассоциация онкологов России. Клинические рекомендации по лечению больных раком молочной железы. Режим доступа: http://www. oncology.ru/association/clinical-guidelines/, свободный.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Поддубная И.В. и др. Популяционный «портрет» рака молочной железы в России: анализ данных российского регистра. Современная онкология. М., 2015.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Zelman AB, Oregon RM. Optimizing endocrine therapy for breast cancer. Journal of the National Comprehensive Cancer Network. 2015, 13(8): 56-64.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>O'Sullivan, Ciara C. Overcoming endocrine resistance in hormone-receptor positive advanced breast cancer-the emerging role of CDK4/6 inhibitors. International journal of cancer and clinical research 2. 2015, 4.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Официальный сайт Novartis. Режим доступа: https://www.novartis.ru, свободный.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Hortobagyi GN et al. American Society of Clinical Oncology. Chicago, IL, USA. Poster 1038. 2017, 2-6.</mixed-citation></ref></ref-list></back></article>
